

Course Code: 23MB1CO5
BONAM VENKATA CHALAMAYYA INSTITUTE OF TECHNOLOGY &
SCIENCE(AUTONOMOUS)

I-MBAI-Semester Supplementary Examinations (BR23), February - 2026

LEGAL AND BUSINESS ENVIRONMENT

Time: 3 hours

Max. Marks: 70

PART - A Answer ONE Question from each UNIT (5 x 12 = 60 Marks)

All Questions Carry Equal Marks

PART - B Compulsory (1 x 10 = 10 Marks)

PART -A

UNIT-I

1. Define Business Environment? Explain different factors influence the Business Environment.

Marks 12M CO CO1 BL BL1

OR

2. What do you understand by Environmental Scanning and explain the process of Environmental Scanning.

12M CO1 BL1

UNIT-II

3. What is Economic System? Explain the features of different types of Economic Systems.

Marks 12M CO CO2 BL BL1

OR

- 4.a) Describe the nature and significance of Indian Economy.
b) What are the objectives of Economic Planning?

6M CO2 BL2
6M CO2 BL1

UNIT-III

5. Explain important features of Negotiable Instruments Act 1881.

Marks 12M CO CO3 BL BL2

OR

6. What do you understand by Breach of Contract and explain its remedies?

12M CO3 BL1

UNIT-IV

7. What is Partnership Act 1932? Explain the duties and responsibilities of Partners.

Marks 12M CO CO4 BL BL1

OR

8. What do you understand by Information Technology Act 2000? Explain its importance.

12M CO4 BL1

UNIT-V

- 9.a) What do you understand by Sale of Goods Act, 1930? Explain its features.

Marks 6M CO CO5 BL BL1

- b) State the differences between Sale and Agreement to Sale.

6M CO5 BL4

OR

10. What is Environment Protection Act 1986? Write its features and importance.

12M CO5 BL1

PART – B

CASE STUDY

Marks CO BL

11 Apex Pharmaceutical India, a giant in the pharmaceutical market, achieved a sale growth of 26% in 2022-23 at about Rs.1,435 crore, its net profit rose by 60% from Rs. 118 crore in 2021-22 to Rs. 188 crore in 2022-23. Apex Pharmaceutical India had a different growth strategy as it started as a small player with big dreams. The strategy was organic growth coupled with acquisitions. Apex Pharmaceutical acquired nine entities and integrated them quickly into the parent company to deliver higher growth from the acquired portfolio.

Apex Pharmaceutical India is also focusing on exports market. It has decided to partner with innovator companies in global markets, rather than compete or patent litigate against them. Building on this base, the company has built an export model that delivers the 'India advantage' to the global firms. It plans to provide end-to-end outsourcing solutions across the pharmaceutical life cycle, from custom-made synthesis and bulk intermediates to formulations. It has established four process development groups at multiple locations in India and has also setup a 100% subsidiary in the US for closer customer reach. Apex Pharmaceutical India believes that the future growth driver will be exports, ably supported by a strong domestic market.

10M CO6 BL4

Questions:

- (a) What are the growth strategies formulated by Apex Pharmaceutical India to explore the opportunities?
- (b) What are the risk factors that the company may face in international market?
